Premium
Circulatory changes of the novel adipokine adipolin/ CTRP 12 in response to metformin treatment and an oral glucose challenge in humans
Author(s) -
Tan Bee K.,
Chen Jing,
Hu Jiamiao,
Amar Omar,
Mattu Harman S.,
Ramanjaneya Manjunath,
Patel Vanlata,
Lehnert Hendrik,
Randeva Harpal S.
Publication year - 2014
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12438
Subject(s) - metformin , adipokine , medicine , endocrinology , polycystic ovary , diabetes mellitus , obesity , insulin , insulin resistance
Summary Objective Adipolin/ CTRP 12 is a novel adipokine with anti‐inflammatory and glucose‐lowering properties in rodents. We sought to investigate the effects of metformin treatment (850 mg twice daily for 6 months) and a 2 h 75 g oral glucose tolerance test ( OGTT ) on serum adipolin concentrations in humans. Design Cross‐sectional study [ PCOS ( n = 83) and control ( n = 39) subjects]. Serum adipolin was measured by ELISA . Metformin treatment (850 mg twice daily for 6 months) was offered to all women with PCOS , 34 women participated but 21 women completed 6 months of metformin therapy. Reasons for subjects not completing the study were nausea and gastrointestinal side effects ( n = 4), pregnancies ( n = 5), noncompliance ( n = 2) and loss of contact ( n = 2). Results Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations ( P < 0·05) in women with polycystic ovary syndrome ( PCOS ), a pro‐inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis. Furthermore, changes in waist‐hip ratio, glucose, triglycerides, CRP and carotid intima media thickness showed significant negative associations with changes in adipolin levels ( P < 0·05, P < 0·01); in multiple regression analyses, only changes in glucose were predictive of changes in adipolin levels (β = −0·570, P = 0·009). Serum adipolin decreased significantly in response to the OGTT in PCOS and control subjects at 90 min ( P < 0·05) and 120 min ( P < 0·01). Conclusions Adipolin and/or novel pharmacologic agents that increase adipolin's circulating concentrations might constitute a novel approach in the treatment of insulin resistant states.